PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 3, 2026Journal of Medicinal Chemistry0 citations

Discovery of YTB53, a Marine-Derived MNK-Active Anti-Acute Myeloid Leukemia Lead with Multi-Kinase Activity

View Full Paper
XCXiang ChenLZLiting ZhangYHYuqiang Han

Key Points

  • The aim is to identify and optimize YTB53 as a potential therapy for acute myeloid leukemia (AML).
  • Discovery of YTB53 through marine sources.
  • Evaluation of its anti-AML properties and kinase activity.
  • Plans for medicinal chemistry optimization to enhance pharmacokinetics.
  • YTB53 exhibits promising anti-AML activity.
  • Demonstrates multi-kinase activity relevant for AML treatment.

Abstract

as a promising multimechanistic lead for AML therapy, warranting further medicinal chemistry optimization to improve its pharmacokinetic properties and advance its development potential.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a1fc616dee9eb8c0dce746bhttps://doi.org/10.1021/acs.jmedchem.6c00387
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of D25, a Potent and Selective MNK Inhibitor for Sepsis-Associated Acute Spleen Injury2024 · 13 citations
  2. 2Design, Synthesis and Evaluation of Novel Phorbazole C Derivatives as MNK Inhibitors through Virtual High-Throughput Screening2022 · 9 citations
  3. 3Metabolic regulation of the bone marrow microenvironment in leukemia2020 · 45 citations
  4. 4Practical oxazole synthesis mediated by iodine from α-bromoketones and benzylamine derivatives2013 · 50 citations
  5. 5Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia2015 · 49 citations